Atorvastatin Monitoring Schedule: Labs, Liver Tests & Follow-Up Exams

What the label actually says to monitor

The Lipitor label says to take atorvastatin once daily at any time of day, with or without food, and to assess LDL-C when clinically appropriate, as early as 4 weeks after starting, then adjust the dose if needed [1]. For the liver, it says to consider liver enzyme testing before initiation and when clinically indicated thereafter [1]. Beyond those two steps, the label's monitoring language centers on muscle symptoms and on certain interacting drugs [1].

Liver tests: before treatment and when clinically indicated

Persistent transaminase elevations above 3 times the upper limit of normal occurred in about 0.7% of patients on atorvastatin in clinical trials; by dose, the rates were 0.2% at 10 mg, 0.2% at 20 mg, 0.6% at 40 mg and 2.3% at 80 mg [1]. In TNT, persistent elevations were 1.3% on 80 mg and 0.2% on 10 mg [1]. Rare fatal and non-fatal hepatic failure has been reported with statins, including atorvastatin [1]. The label's liver contraindications are acute liver failure and decompensated cirrhosis [1]. It says to promptly discontinue Lipitor if serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs [1].

LDL-C follow-up: the 4-week check

In pooled six-week data, mean LDL-C reductions ranged from 39% at 10 mg to 60% at 80 mg [1]. Patients who need an LDL-C reduction greater than 45% may start at 40 mg [1].

Muscle symptoms and CK

The label warns about myopathy and rhabdomyolysis and lists risk factors: age 65 or older, uncontrolled hypothyroidism, renal impairment, interacting drugs and higher atorvastatin dose [1]. It instructs patients to promptly report unexplained muscle pain, tenderness or weakness, particularly with malaise or fever [1]. The label says to discontinue Lipitor if markedly elevated CK levels occur or if myopathy is diagnosed or suspected [1]. Rare immune-mediated necrotizing myopathy has been reported; the label says to discontinue if it is suspected [1]. In STOMP, 420 healthy statin-naive people took atorvastatin 80 mg or placebo for 6 months; no individual CK value exceeded 10 times normal, average CK rose 20.8 U/L with atorvastatin, and more atorvastatin than placebo subjects developed myalgia (19 vs 10) [2].

Blood sugar and HbA1c

The label reports increases in HbA1c and fasting serum glucose with statins, including atorvastatin, and advises optimizing lifestyle measures [1]. In SPARCL, diabetes was reported as an adverse reaction in 6.1% of subjects on atorvastatin 80 mg and 3.8% on placebo [1]. The label does not give an HbA1c testing interval [1].

Drug interactions that change follow-up

Atorvastatin is a CYP3A4 substrate [1]. Clarithromycin 500 mg twice daily raised atorvastatin AUC 4.54-fold, and itraconazole 200 mg daily raised it 3.32-fold; with either drug, the label says not to exceed atorvastatin 20 mg daily [1]. Nelfinavir has a 40 mg cap [1]. Cyclosporine and gemfibrozil are not recommended; cyclosporine 5.2 mg/kg/day raised atorvastatin 10 mg AUC 8.69-fold [1]. The label says to avoid large quantities of grapefruit juice, more than 1.2 liters daily [1]. It also says to give atorvastatin and rifampin at the same time, and to monitor digoxin when atorvastatin 80 mg is used [1].

Monitoring with interacting drugs

With certain interacting antivirals, azole antifungals or macrolide antibiotics, the label calls for monitoring for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug [1]. For fibrates other than gemfibrozil, lipid-modifying niacin doses and colchicine, it says to weigh benefit against the added myopathy risk and, if used together, to monitor in the same way [1].